772 research outputs found
Band FM of Journalism of São Paulo – Emergence and consolidation of a new segment and a new audience
Young open clusters in the galactic star forming region NGC 6357
NGC6357 is an active star forming region with very young massive open
clusters (OC). These clusters contain some of the most massive stars in the
Galaxy and strongly interact with nearby giant molecular clouds (GMC). We study
the young stellar populations of the region and of the OC Pismis24, focusing on
their relationship with the nearby GMCs. We seek evidence of triggered star
formation propagating from the clusters. We used new deep JHKs photometry,
along with unpublished deep IRAC/Spitzer MIR photometry, complemented with
optical HST/WFPC2 high spatial resolution photometry and X-ray Chandra
observations, to constrain age, initial mass function, and star formation modes
in progress. We carefully examine and discuss all sources of bias (saturation,
confusion, different sensitivities, extinction). NGC6357 hosts three large
young stellar clusters, of which Pismis24 is the most prominent. We found that
Pismis24 is a very young (~1-3 Myr) OC with a Salpeter-like IMF and a few
thousand members. A comparison between optical and IR photometry indicates that
the fraction of members with a NIR excess (i. e., with a circumstellar disk) is
in the range 0.3-0.6, consistent with its photometrically derived age. We also
find that Pismis24 is likely subdivided into a few different sub-clusters, one
of which contains almost all the massive members. There are indications of
current star formation triggered by these massive stars, but clear age trends
could not be derived (although the fraction of stars with a NIR excess does
increase towards the HII region associated with the cluster). The gas out of
which Pismis24 formed must have been distributed in dense clumps within a cloud
of less dense gas ~1 pc in radius. Our findings provide some new insight into
how young stellar populations and massive stars emerge, and evolve in the first
few Myr after birth, from a giant molecular cloud complex.Comment: 34 pages, 26 figures, to be published in Astronomy & Astrophysic
Extensive Characterization of Platelet Gel Releasate From Cord Blood in Regenerative Medicine.
Platelet gel derived from peripheral blood is widely applied in many clinical fields of surgery as biomaterial containing growth factors with high proliferative properties. In 2010, we studied and patented a platelet gel derived from cord blood. In this study, due to the crucial role of the factors released by the platelet gel, we first extended the characterization of its releasate. Using a wide proteomic array and splitting the two components of the releasate, that is, platelets and plasma, we have been able to study their growth factor content. Interestingly, we discovered high levels of hormones and molecules able to support tissue growth in the cord blood platelet gel releasate and, in addition, higher concentrations of several angiogenic factors if compared with the peripheral blood counterpart. On the contrary, the latter was much richer in inflammatory factors. The second aim of our work was to study the effects on cell culture, immunophenotype, and function of mesenchymal stem cells exposed to these two platelet gel releasates as substitute for the animal serum. Since our findings nicely show that the use of the peripheral versus the cord blood platelet gel releasate can differently influence the mesenchymal stem cell commitment, we can suggest that in addition to its peculiar angiogenic properties cord blood platelet gel releasate shows excellent proliferative properties as cell culture supplement
The Healthy Fatty Index Allows for Deeper Insights into the Lipid Composition of Foods of Animal Origin When Compared with the Atherogenic and Thrombogenicity Indexes
The aim of this research was to validate the effectiveness of the Healthy Fatty Index (HFI) regarding some foods of animal origin (meat, processed, fish, milk products, and eggs) typical of the Western diet and to compare these results with two consolidated indices (atherogenic-AI, and thrombogenic-TI) in the characterization of the nutritional features of their lipids. The fatty acids profile (% of total fatty acids and mg/100 g) of 60 foods, grouped in six subclasses, was used. The AI, TI, and HFI indexes were calculated, and the intraclass correlation coefficients and the degree of agreement were evaluated using different statistical approaches. The results demonstrated that HFI, with respect to AI and TI, seems better able to consider the complexity of the fatty acid profile and the different fat contents. HFI and AI are the two most diverse indices, and they can provide different food classifications. AI and IT exhibit only a fair agreement in regards to food classification, confirming that such indexes are always to be considered indissolubly and never separately, in contrast to the HFI, which can stand alone
Integration of art and technology in personalized radiation oncology care: Experiences, evidence, and perspectives
Cancer diagnoses expose patients to traumatic stress, sudden changes in daily life, changes in the body and autonomy, with even long-term consequences, and in some cases, to come to terms with the end-of-life. Furthermore, rising survival rates underline that the need for interventions for emotional wellbeing is in growing demand by patients and survivors. Cancer patients frequently have compliance problems, difficulties during treatment, stress, or challenges in implementing healthy behaviors. This scenario was highlighted during the COVID-19 emergency. These issues often do not reach the clinical attention of dedicated professionals and could also become a source of stress or burnout for professionals. So, these consequences are evident on individual, interpersonal, and health system levels. Oncology services have increasingly sought to provide value-based health care, considering resources invested, with implications for service delivery and related financing mechanisms. Value-based health care can improve patient outcomes, often revealed by patient outcome measures while seeking balance with economical budgets. The paper aims to show the Gemelli Advanced Radiation Therapy (ART) experience of personalizing the patients' care pathway through interventions based on technologies and art, the personalized approach to cancer patients and their role as “co-stars” in treatment care. The paper describes the vision, experiences, and evidence that have guided clinical choices involving patients and professionals in a co-constructed therapeutic pathway. We will explore this approach by describing: the various initiatives already implemented and prospects, with particular attention to the economic sustainability of the paths proposed to patients; the several pathways of personalized care, both from the patient's and healthcare professional perspective, that put the person's experience at the Gemelli ART Center. The patient's satisfaction with the treatment and economic outcomes have been considered. The experiences and future perspectives described in the manuscript will focus on the value of people's experiences and patient satisfaction indicators, patients, staff, and the healthcare organization
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters
Recently, many reports were published supporting the clinical use of adoptivelytransferred natural killer (NK) cells as a therapeutic tool against cancer, including acutemyeloid leukemia (AML). Our group demonstrated promising clinical response usingadoptive immunotherapy with donor-derived alloreactive KIR-ligand-mismatched NK cellsin AML patients. Moreover, the antileukemic effect was correlated with the dose of infusedalloreactive NK cells (“functional NK cell dose”). Herein, we update the results of ourprevious study on a cohort of adult AML patients (median age at enrollment 64) infirstmorphological complete remission (CR), not eligible for allogeneic stem celltransplantation. After an extended median follow-up of 55.5 months, 8/16 evaluablepatients (50%) are still off-therapy and alive disease-free. Overall survival (OS) and disease-free survival (DFS) are related with the dose of infused alloreactive NK cells (≥2×105/kg
Inter-rater agreement of CDC criteria and ASEPSIS score in assessing surgical site infections after cesarean section: a prospective observational study
ObjectiveTo assess and compare the inter-rater agreement of the CDC criteria and the ASEPSIS score in identifying surgical site infections after cesarean section.MethodsProspective observational study including 110 patients subjected to a cesarean section at our institution. Surgical wounds were managed according to standard care and were photographed on the third, seventh, and thirtieth postoperative day or during any evaluation in case of complications. Three expert surgeons reviewed the prospectively gathered data and photographs and classified each wound using CDC criteria and the ASEPSIS score. The inter-rater agreements of CDC criteria and ASEPSIS score were determined with Krippendorff's Alpha with linear weights and compared with a confidence interval approach.ResultsThe weighted α coefficient for CDC criteria was 0.587 (95%CI, 0.411–0.763, p < 0.001, “moderate” agreement according to Altman's interpretation of weighted agreement coefficient), while the weighted α coefficient for the ASEPSIS score was 0.856 (95%CI, 0.733–0.980, p < 0.001, “very good” agreement).ConclusionASEPSIS score presents a “very good” inter-rater agreement for surgical site infections identification after cesarean, resulting in a more objective method than CDC criteria (“moderate” inter-rater agreement). ASEPSIS score could represent an objective tool for managing and monitoring surgical site infections after cesarean section, also by photographic evaluation
Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia
Pregnancy in women with inherited thrombocytopenias is a major matter of concern as both the mothers and the newborns are potentially at risk of bleeding. However, medical management of this condition cannot be based on evidence because of the lack of consistent information in the literature. To advance knowledge on this matter, we performed a multicentric, retrospective study evaluating 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. Neither the degree of thrombocytopenia nor the severity of bleeding tendency worsened during pregnancy and the course of pregnancy did not differ from that of healthy subjects in terms of miscarriages, fetal bleeding and pre-term births. The degree of thrombocytopenia in the babies was similar to that in the mother. Only 7 of 156 affected newborns had delivery-related bleeding, but 2 of them died of cerebral hemorrhage. The frequency of delivery-related maternal bleeding ranged from 6.8% to 14.2% depending on the definition of abnormal blood loss, suggesting that the risk of abnormal blood loss was increased with respect to the general population. However, no mother died or had to undergo hysterectomy to arrest bleeding. The search for parameters predicting delivery-related bleeding in the mother suggested that hemorrhages requiring blood transfusion were more frequent in women with history of severe bleedings before pregnancy and with platelet count at delivery below 50 Ă— 10(9)/L.Fil: Noris, Patrizia. Istituti di Ricovero e Cura a Carattere Scientifico. Policlinico San Matteo di Pavia; Italia. UniversitĂ degli Studi di Pavia; ItaliaFil: Schlegel, Nicole. UniversitĂ© Paris Diderot - Paris 7; FranciaFil: Klersy, Catherine. Istituti di Ricovero e Cura a Carattere Scientifico. Policlinico San Matteo di Pavia; ItaliaFil: Heller, Paula Graciela. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Houssay. Instituto de Investigaciones MĂ©dicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones MĂ©dicas; ArgentinaFil: Civaschi, Elisa. UniversitĂ degli Studi di Pavia; ItaliaFil: Pujol Moix, Nuria. Universitat Autònoma de Barcelona; EspañaFil: Fabris, Fabrizio. UniversitĂ di Padova; ItaliaFil: Favier, Remi. Inserm; Francia. Armand Trousseau Children’s Hospital; Francia. French Reference Center for Inherited Platelet disorders; FranciaFil: Gresele, Paolo. UniversitĂ di Perugia; ItaliaFil: Latger Cannard, VĂ©ronique. Centre Hospitalo-Universitaire. Service d’HĂ©matologie Biologique; Francia. Reference French Centre. Centre de CompĂ©tence Nord-Est des Pathologies Plaquettaires; FranciaFil: Cuker, Adam. University of Pennsylvania; Estados UnidosFil: Nurden, Paquita. HĂ´pital Xavier Arnozan; FranciaFil: Greinacher, Andreas. Institut fĂĽr Immunologie und Transfusionsmedizin; AlemaniaFil: Cattaneo, Marco. UniversitĂ degli Studi di Milano; ItaliaFil: De Candia, Erica. UniversitĂ Cattolica del Sacro Cuore; ItaliaFil: Pecci, Alessandro. UniversitĂ degli Studi di Pavia; ItaliaFil: Hurtaud Roux, Marie Françoise. UniversitĂ© Paris Diderot - Paris 7; FranciaFil: Glembotsky, Ana Claudia. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Houssay. Instituto de Investigaciones MĂ©dicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones MĂ©dicas; ArgentinaFil: Muñiz Diaz, Eduardo. Banc de Sang i Teixits de Catalunya. Immunohematology Department; EspañaFil: Randi, Maria Luigia. UniversitĂ di Padova; ItaliaFil: Trillot, Nathalie. Centre Hospitalier RĂ©gional Universitaire de Lille. PĂ´le Biologie Pathologie GĂ©nĂ©tique. Institut d’HĂ©matologie-Transfusion; FranciaFil: Bury, Loredana. UniversitĂ di Perugia; ItaliaFil: Lecompte, Thomas. HĂ´pitaux Universitaires de Genève; Suiza. UniversitĂ© de Genève. FacultĂ© de MĂ©decine; SuizaFil: Marconi, Caterina. UniversitĂ di Bologna; ItaliaFil: Savoia, Anna. UniversitĂ degli Studi di Trieste; ItaliaFil: Balduini, Carlo L.. Istituti di Ricovero e Cura a Carattere Scientifico Burlo Garofolo. Institute for Maternal and Child Health; Italia. UniversitĂ degli Studi di Pavia; ItaliaFil: European Hematology Association Scientific Working Group on Thrombocytopenias and Platelet Function Disorders. No especifica
Identification of New Hematopoietic Cell Subsets with a Polyclonal Antibody Library Specific for Neglected Proteins
The identification of new markers, the expression of which defines new phenotipically and functionally distinct cell subsets, is a main objective in cell biology. We have addressed the issue of identifying new cell specific markers with a reverse proteomic approach whereby approximately 1700 human open reading frames encoding proteins predicted to be transmembrane or secreted have been selected in silico for being poorly known, cloned and expressed in bacteria. These proteins have been purified and used to immunize mice with the aim of obtaining polyclonal antisera mostly specific for linear epitopes. Such a library, made of about 1600 different polyclonal antisera, has been obtained and screened by flow cytometry on cord blood derived CD34+CD45dim cells and on peripheral blood derived mature lymphocytes (PBLs). We identified three new proteins expressed by fractions of CD34+CD45dim cells and eight new proteins expressed by fractions of PBLs. Remarkably, we identified proteins the presence of which had not been demonstrated previously by transcriptomic analysis. From the functional point of view, looking at new proteins expressed on CD34+CD45dim cells, we identified one cell surface protein (MOSC-1) the expression of which on a minority of CD34+ progenitors marks those CD34+CD45dim cells that will go toward monocyte/granulocyte differentiation. In conclusion, we show a new way of looking at the membranome by assessing expression of generally neglected proteins with a library of polyclonal antisera, and in so doing we have identified new potential subsets of hematopoietic progenitors and of mature PBLs
- …